Nuvation Bio Inc [NUVB] stock is trading at $3.01, up 4.51%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NUVB shares have gain 31.44% over the last week, with a monthly amount glided 32.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on March 27, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $10 from $1.40. Previously, BTIG Research upgraded its rating to Buy on March 26, 2024, and kept the price target unchanged to $5. On January 06, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. BTIG Research downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2.50 on August 02, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 04, 2022, and assigned it a price target of $14.
Nuvation Bio Inc [NUVB] stock has fluctuated between $1.21 and $4.16 over the past year. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $3.01 at the most recent close of the market. An investor can expect a potential return of 124.25% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
Gross Profit Margin for this corporation currently stands at -0.33% with Operating Profit Margin at -55.42%, Pretax Profit Margin comes in at -219.41%, and Net Profit Margin reading is -219.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is -1.09 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.87 points at the first support level, and at 2.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.11, and for the 2nd resistance point, it is at 3.22.
Ratios To Look Out For
For context, Nuvation Bio Inc’s Current Ratio is 9.57. In addition, the Quick Ratio stands at 9.57 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 517.09, the price to book ratio is 2.01.
Transactions by insiders
Recent insider trading involved Mashal Robert, Director, that happened on Oct 08 ’24 when 100000.0 shares were purchased. Director, Cui Xiangmin completed a deal on Jun 25 ’24 to buy 0.28 million shares. Meanwhile, Director Cui Xiangmin bought 0.34 million shares on Jun 24 ’24.
